Abstract

The role of the C-1019G variant in conferring susceptibility to mood disorders is an object of ongoing debate. In their recent meta-analysis of case–control investigations, Kishi and coworkers have sought to clarify the issue by pooling earlier results. Whether a claimed effect of this variant can be upheld, however, is questionable in view of numerous artefacts.